SNT.ASX: Encouraging SNT-4728 Phase 2 iRBD results

Encouraging SNT-4728 Phase 2 iRBD results

Stock	Syntara Ltd (SNT.ASX)
Release Time	6 Jul 2026, 9:43 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Syntara Announces Encouraging Phase 2 iRBD Study Results for SNT-4728

Key Points

Statistically significant reduction in brain inflammation in the putamen
20 out of 30 patients on active treatment showed reduced inflammation
Full results and additional analyses expected in Q3 2026

Full Summary

Syntara Limited (ASX: SNT) has announced preliminary results from its Phase 2 clinical trial of SNT-4728, a neuro-targeted anti-inflammatory therapy, in patients with isolated REM Sleep Behaviour Disorder (iRBD). The study, the first interventional trial targeting neuroinflammation in iRBD, demonstrated a statistically significant reduction in brain inflammation in the putamen, a region associated with Parkinson's Disease motor symptoms. The results, observed in 20 out of 30 patients on active treatment, suggest that SNT-4728 may modulate disease-relevant neuroinflammatory pathways. The trial was safe and well-tolerated, with no treatment-related serious adverse events reported. Full results, including additional analyses, are expected in Q3 2026.

Outlook

Syntara plans to release full results from the study in Q3 2026, which will provide further insights into the drug's efficacy and safety profile.